Originally published at www.seclive.com
Filing in Focus: Aeolus 10-K, December 20, 2013
Aeolus Pharmaceuticals Inc. (OTCQB:AOLS) announced its financial results for the full fiscal year 2013, posting a net loss of $3.21M, or $0.03 losses per share. The biotechnology company, which develops chemical compounds to counter radiological and chemical threats, receives a large portion of its funding from the U.S. Government. The company's large decreases in revenue as well as research and development costs were due mostly to the timing of certain program items under the Biomedical Advanced Research and Development Authority (BARDA) contract. Aeolus continues to develop and refine its flagship AEOL 10150 compound, which could be used to the benefit of those exposed, or about to be exposed, to high doses of radiation during oncology treatment. President and CEO John McManus commented that progress of its 10150 compound was very encouraging and that 2014 will be yet another exciting year as more testing and results are published on the chemical's effectiveness.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.